Litigation

Recent Posts

Jury Awards $1.3 Million In Zometa Jaw Injury Trial After Botching 1st Verdict Form
Posted on 23 Sep 2013 by Tom Moylan

ORLANDO, Fla. — (Mealey’s) A Florida federal jury on Sept. 20 found that Novartis Pharmaceuticals Corp. failed to warn a cancer patient about the risk of osteonecrosis of the jaw (ONJ) and awarded her $1.3 million in medical expenses and non... Read More

Jury Awards Plaintiff $10.4 Million For Injuries, Punitive Damages Linked To Novartis' Zometa
Posted on 5 Nov 2012 by Tom Moylan

CENTRAL ISLIP, N.Y. - (Mealey's) A New York federal jury on Nov. 2 found Novartis Pharmaceuticals Corp. liable for a woman's osteonecrosis of the jaw (ONJ) and awarded her $10.45 million, according to the parties ( Barbara Davids v. Novartis Pharmaceuticals... Read More

2nd Fosamax Bellwether Plaintiff Failed To Prove Causation, 2nd Circuit Affirms
Posted on 8 Nov 2010 by Tom Moylan

NEW YORK - (Mealey's) The second bellwether plaintiff in the Fosamax multidistrict litigation failed to produce evidence that the osteoporosis drug caused her osteonecrosis of the jaw (ONJ), a panel of the Second Circuit U.S. Court of Appeals ruled... Read More

Novartis Wins Defense Verdict In Zometa Jaw Injury Trial
Posted on 26 May 2011 by Tom Moylan

BROOKLYN, N.Y. (Mealey's) A New York federal jury in the first federal Zometa trial found May 25 that the plaintiff did not prove by a preponderance of evidence that the Novartis Pharmaceuticals Corp. drug caused a decedent's osteonecrosis of... Read More

Merck To Settle Suits Alleging Jaw Damage From Osteoporosis Drug
Posted on 10 Dec 2013 by Michael Lefkowitz

WHITEHOUSE STATION, N.J. — (Mealey's) Merck & Co. Inc. has agreed to pay $27.7 million to resolve product liability suits alleging that its osteoporosis drug Fosamax caused osteonecrosis of the jaw (ONJ), or bone death, according to a press... Read More